Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nal-IRI + 5-FU/LV + Oxaliplatin in Metastatic Pancreatic Cancer
NCT02551991Phase 2Completed
- Sponsor
- Ipsen
- Start
- Oct 2015
- Primary completion
- Feb 2021
- Modality
- Lipid-based Nanoparticles, Small Molecules
- Countries
- 3
01
Overview
Phase 2, open-label, single-arm trial of irinotecan liposome in pancreatic adenocarcinoma (PDAC), sponsored by Ipsen. Primary endpoint: Dose-Limiting Toxicities. Started Oct 2015; status: completed.
02
Drugs
irinotecan liposome
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT02551991.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02551991.